SCHEMBL6224375

SCHEMBL6224375

O=C(NCC1CCCCN1)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.47
CYP2D6 P10635 4/20 0.46
LMNA P02545 4/20 0.46
CYP1A2 P05177 3/20 0.46
TSHR P16473 2/20 0.46
SLC6A2 P23975 2/20 0.46
KCNH2 Q12809 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CACNA1F O60840 1/20 0.46
KCNA5 P22460 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRK1 P41145 1/20 0.46
CACNA1D Q01668 1/20 0.46
CACNA1S Q13698 1/20 0.46
CACNA1C Q13936 1/20 0.46
SCN5A Q14524 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22439432 1.00 SCN9A (0.47) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL1599013 1.00 SCN9A (0.47) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL1597624 0.95 SCN9A (0.43) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL871030 0.95 SCN9A (0.43) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL871031 0.95 SCN9A (0.43) SCN9ACYP2D6LMNACYP1A2TSHR
Hydrochloric Acid SCHEMBL3040950 0.93 SCN9A (0.42) SCN9ACYP2D6LMNACYP1A2TSHR
Hydrochloric Acid SCHEMBL3040954 0.93 SCN9A (0.42) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL20186812 0.79 FDPS (0.47) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL3088560 0.79 FDPS (0.47) SCN9ACYP2D6LMNACYP1A2TSHR
SCHEMBL1598094 0.79 FDPS (0.47) SCN9ACYP2D6LMNACYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265134-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-09-04 US disclosed
US-7265134-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-09-04 US disclosed
EP-1289955-B1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2005-04-13 EP disclosed
US-6677354-B2 TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-01-13 US disclosed
US-20030186964-A1 Piperdines for use as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-02 US disclosed
EP-1289955-A1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2003-03-12 EP disclosed
WO-2001096302-A1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186964-A1 Piperdines for use as orexin receptor antagonists HCRTR2, HCRTR1, NPSR1 SCN9A 218/4885CYP2D6 578/4885LMNA 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.